Italy-based BMG Pharma has signed an exclusive distribution agreement with Samyang Biopharmaceutical for its novel mucositis management product, GelX.

As part of the deal, Samyang receives the rights to promote, sell and market the product in two different formulations GelX oral gel 300ml and GelX Oral spray 100ml in South Korea, as well as make an undisclosed down payment to BMG Pharma.

BMG Pharma said that GelX will help patients receive the best care possible by using a new delivery technology to provide fast pain relief and reduce swallowing issues and discomfort related with mucositis related to chemotherapy, radiotherapy and other pharmacologic therapies.

"Samyang receives the rights to promote, sell and market the product in two different formulations GelX oral gel 300ml and GelX Oral spray 100ml in South Korea."

BMG Pharma president and CEO Marco Mastrodonato said: "BMG’s team were the originator of some of the major Rx medical devices in cancer supportive care, including Radiation Dermatitis and Xerostomia, and we are sure we are providing the market with a new generation of innovative products for support of cancer patients and we are very pleased of the commitment from a major company like SAMYANG for GelX."

BMG Pharma claims that the delivery technology associated with GelX is a significant breakthrough in ease of use and compliance associated with patients presenting with especially chemotherapy/radiotherapy-induced oral mucositis.

Samyang Biopharmaceutical president Cheolho Kwak said: "We are very pleased to work with BMG Pharma Srl to launch GelX in the South Korean market."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to BMG Pharma, both GelX oral gel and spray have a mechanical action indicated for the management and relief of pain by adhering to the mucosal surface of the mouth, soothing the lesions caused by chemotherapy and/or radiation therapy.

Compared with the existing marketed products, GelX in both formulations is designated to benefit patients by improving the convenience, efficacy and compliance.